Skip to main content

4 Result(s)

within Paul M. O’Byrne Remove this filter Biomedicine Remove this filter English Remove this filter

and

  1. No Access

    Chapter

    Anti-IgE and Biologic Approaches for the Treatment of Asthma

    Current asthma treatments are effective for the majority of patients with mild-to-moderate disease. However, in those with more severe refractory asthma, agents other than inhaled corticosteroids and beta-agon...

    Patrick D. Mitchell, Amani I. El-Gammal… in Pharmacology and Therapeutics of Asthma an… (2017)

  2. Article

    Open Access

    Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

    Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (...

    Jan Lötvall, Eric D Bateman, William W Busse… in Journal of Negative Results in BioMedicine (2014)

    Download PDF (608 KB) View Article

  3. No Access

    Article

    The pharmacological modulation of allergen-induced asthma

    Aeroallergens are the most common triggers for the development of asthma. Recent birth cohort studies have identified viral infections occurring against a background of aeroallergen sensitization as a potent r...

    L. L. Ma, Paul M. O’Byrne in Inflammopharmacology (2013)

  4. No Access

    Article

    A GABAergic system in airway epithelium is essential for mucus overproduction in asthma

    γ-Aminobutyric acid (GABA) is an important neurotransmitter that, through the subtype A GABA receptor (GABAAR), induces inhibition in the adult brain. Here we show that an excitatory, rather than inhibitory, GABA...

    Yun-Yan **ang, Shuhe Wang, Mingyao Liu, Jeremy A Hirota, **gxin Li… in Nature Medicine (2007)